Previous close | 6.52 |
Open | 6.47 |
Bid | 6.48 x 1000 |
Ask | 6.49 x 900 |
Day's range | 6.39 - 6.60 |
52-week range | 5.31 - 22.69 |
Volume | |
Avg. volume | 1,136,511 |
Market cap | 361.694M |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Growth stocks have lost momentum in August after a strong start to the year. Innovative companies in the fields of drug development and medical imaging, such as Agenus (NASDAQ: AGEN), BioCryst Pharmaceuticals (NASDAQ: BCRX), and Nano-X Imaging (NASDAQ: NNOX) have all experienced a significant drop in their stock prices in the past 30 days.
Nano-X Imaging ( NASDAQ:NNOX ) Second Quarter 2023 Results Key Financial Results Net loss: US$17.4m (loss narrowed by...
Earlier today, Nano-X Imaging Limited released financial results for the quarter ended June 30, 2023. Erez Meltzer, chief executive officer; and Ran Daniel, chief financial officer, will host this morning's call.